George W. Sledge, MD

2009-2010 BCRF Project:
BCRF-funded studies at Indiana University led to crucial proof-of concept trials targeting new blood vessel formation (anti-angiogenic therapy). Dr. Sledge and his team are currently examining 1) the interaction of subtle genetic changes in the host (called single nucleotide polymorphisms) with new blood vessel formation in breast cancer patients; 2) the development of resistance to VEGF- targeting agents, and means by which the development of resistance to these agents might be prevented.

In the coming year, the researchers will focus on novel aspects of breast cancer angiogenesis. They aim to understand the role of bevacizumab-induced effects on host biology as well as on tumor biology by analyzing plasma miRNA profiles in vivo. They will also investigate the mechanisms of bevacizumab therapy with novel targets to decrease the drug-induced invasive phenotype in breast cancer.

Mid-Year Progress Report:
Dr. Sledge and his colleagues have focused on two aspects of work during the current funding period. 1) the interaction of subtle genetic changes in the host (called single nucleotide polymorphisms) with new blood vessel formation in breast cancer patients; and 2) the development of resistance to VEGF-targeting agents, and means by which we might prevent the development of resistance to these agents.

Bio:
Dr. Sledge is the Ballve-Lantero Professor of Oncology and co-director of the breast cancer program at the Indiana University Cancer Center, and a professor of medicine and pathology at Indiana University School of Medicine. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer, particularly the development of anti-angiogenic therapy. He has published numerous articles in medical journals about breast cancer and chaired several nationwide clinical trials involving new breast cancer treatments. Recently, his research has focused on novel biologic therapies.

Dr Sledge serves as Editor-in-Chief of the journal Clinical Breast Cancer, has been a member of the ASCO (American Society of Clinical Oncology) Board of Directors for many years, and has been recently named, ASCO President 2010-2011. He served as chairman of the Breast Committee of the Eastern Cooperative Oncology Group from 2002 - 2009. He was named the recipient of the 2006 Komen Foundation Brinker Award for Scientific Distinction, the 2007 Breast Cancer Research Foundation’s Jill Rose award and was the recipient of the Individual Lifetime Achievement Award - 2009 given by Susan G. Komen for the Cure - Indianapolis Affiliate. He has been a long-time supporter of the Pink Ribbon Connection (formerly known as the Y-Me Organization).